CLINUVEL Pharmaceuticals (ASX:CUV) has presented new evidence of its lead therapy SCENESSE (afamelanotide) delivering visible and lasting repigmentation in patients with vitiligo, one of the world’s most common pigmentary disorders. …
CLINUVEL’s SCENESSE demonstrates promising results in vitiligo patients
September 21, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 7 November
November 7, 2025 - - Podcast -
Donald Trump announces 'MFN' deals with Lilly and Novo Nordisk and end to 'global freeloading'
November 7, 2025 - - Latest News -
Sanofi employees contribute over 400 volunteer hours to community and environmental causes
November 6, 2025 - - Latest News -
Neuren posts record royalties as DAYBUE sales surpass US$100 million in third quarter
November 6, 2025 - - Australian Biotech -
US Ambassador warns UK risks losing pharma investment unless it pays more for medicines
November 6, 2025 - - Latest News -
Pfizer to continue legal fight as court rejects bid to block Novo Nordisk’s Metsera takeover bid
November 6, 2025 - - Latest News -
What next for PBS rebate system amid constitutional breaches, disputed claims, and global pressure?
November 6, 2025 - - Latest News